UK gov rejects FRAND rate-setting track; HDMI LA interview; OPPO takes Via Qi pool license; Novo Nordisk patent revoked; Sony-Meta VR patent transfer; UPC Roundup; more

1) Premium (free summary): UK government rejects new FRAND rate-setting track in SEP policy response

The UK government has rejected a dedicated FRAND rate-setting track in favor of exploring early judicial evaluation and non-binding IPO opinions, while leaving the existing injunction framework unchanged.

2) Premium: HDMI LA’s first IP dispute in decades ‘solidified’ licensing program, Chief Licensing Officer says

Having a judge confirm that everything you are doing is “spot on” affirmed that the program’s fees are fair and reasonable, HDMI LA’s Trudi Bordi tells ip fray in an interview.

3) Free: OPPO, Nidec have taken Qi Wireless Power patent pool license, Via announces during AI licensing-focused Summit

During its annual Bridge Summit in San Francisco, which largely focused on opportunities and strategies in AI patent licensing, Via Licensing Alliance announced Japan’s Nidec Mobility Corporation and China’s OPPO – already a licensor – have both taken a license in Via’s Qi Wireless Power patent pool.

4) Premium: EPO Board of Appeal revokes Novo Nordisk’s cardiovascular semaglutide patent; generics could enter EU as early as 2031

The Board found the claims lacked priority, so a clinical study publication destroyed novelty, leaving Ozempic and Wegovy potentially vulnerable to competition earlier than expected.

5) Premium: UPC Roundup (1 week): CoA clarifies electronic signature requirements; PMAC and UPC accelerate activities on FRAND, AI and dispute resolution; and more

This is a summary of developments in and around the UPC in the calendar week of October 5, 2026. It was a slow week in terms of decisions.

6) Free: Qualcomm-Huawei disagreement reflects inherently subjective nature of unpacking complex “license-plus” deals

Qualcomm’s and Huawei’s divergent interpretations of their license-plus-patent-transfer agreement are just the latest example of how two parties can take different perspectives on the same deal without anyone necessarily lying.

7) Premium: Sony’s 419-patent transfer to Meta indicates major scale-back in VR business

While it is not certain that Sony would completely exit the market, the company has struggled recently. Meanwhile, of the 4.2 million units of AI smart glasses sold in the first half of 2026, 81% (3.4 million) were Meta’s.

8) Premium: InterDigital, Parks Associates claim HDR is becoming a baseline video feature: report lands amid Disney+ feature removals

InterDigital and market research firm Parks Associates have claimed that HDR is heading toward baseline status. But Disney is betting on consumers being more attached to content than picture quality.

9) Premium: MIT enforces cloud and IoT chip security patents against Amazon Web Services, Microsoft in U.S.

The asserted quasi-SEPs relate to physical unclonable function (PUF) technology, which has important applications in authentication and cryptography.

10) Free: Wilus defeats four consecutive Wi-Fi SEP reexaminations, granted additional claims: challenges by Unified Patents

The four consecutive reexamination wins also reinforce the strength of the SEPs in Sisvel’s Wi-Fi patent pool, Chief IP Officer Heath Hoglund noted today.

11) Premium (free summary): SK hynix sues Longhorn IP again, alleging repeated patent demands through affiliates

SK hynix has taken Longhorn IP back to court, challenging infringement allegations over eight former TSMC patents and accusing the licensing company of using a new affiliate to pursue additional licensing demands despite earlier agreements.

12) Premium: Disney hit with Delaware complaint from ETRI over video coding SEPs

ETRI claims that Disney was repeatedly contacted by Access Advance to take a (F)RAND license to the VDP pool, which would cover the asserted patents.

13) Premium: Halozyme wins Dutch injunction against Merck’s Keytruda SC in eight European countries, court holds patent valid

The Hague District Court has upheld Halozyme’s patent and found infringement. Merck’s subcutaneous cancer drug is blocked in eight European countries, but Merck strongly disagrees, alleging the patent is invalid.

14) Premium: BlackBerry acquires Google patents, reports “stronger than expected” licensing revenue

BlackBerry also reported that it received patents as part of a customer contract, though it isn’t clear if that customer could’ve been Google.

15) Premium: ZTE assigns over a hundred more patents to U.S. PAE as Verizon files counterclaim in mobile networking suit

Earlier this year, PAE Eight Deer Ventures asserted patents previously owned by ZTE against Verizon and AT&T in U.S. district court.